Literature DB >> 26882419

Actigraphy-based sleep parameters during the reinstatement of methamphetamine self-administration in rhesus monkeys.

Laís F Berro1, Monica L Andersen1, Sergio Tufik2, Leonard L Howell1.   

Abstract

The objective of this study was to investigate nighttime activity of nonhuman primates during extinction and cue- and drug-primed reinstatement of methamphetamine self-administration. Adult rhesus monkeys (Macaca mulatta; n = 5) self-administered methamphetamine (0.01 mg/kg/injection, i.v.) under a fixed-ratio 20 schedule of reinforcement. Saline infusions were then substituted for methamphetamine and stimulus light (drug-conditioned stimulus presented during drug self-administration) withheld until subjects reached extinction criteria. Drug- and cue-induced reinstatement effects were evaluated after i.v. noncontingent priming injections of methamphetamine (0.03, 0.1, or 0.3 mg/kg). Activity-based sleep measures were evaluated with Actiwatch monitors a week before (baseline nighttime activity parameters) and throughout the protocol. Although methamphetamine self-administration did not significantly affect nighttime activity compared to baseline, sleeplike parameters were improved during extinction compared to self-administration maintenance. Priming injection of 0.1 mg/kg methamphetamine, but not 0.03 or 0.3 mg/kg, induced significant reinstatement effects. These behavioral responses were accompanied by nighttime outcomes, with increased sleep fragmentation and decreased sleep efficiency in the night following 0.1 mg/kg methamphetamine-induced reinstatement. In the absence of both drug and drug-paired cues (extinction conditions), nighttime activity decreased compared to self-administration maintenance. Additionally, effective reinstatement conditions impaired sleeplike measures. Our data indicate that the reintroduction of the stimulus light as a drug-paired cue increased nighttime activity. (c) 2016 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26882419      PMCID: PMC4795967          DOI: 10.1037/pha0000064

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  7 in total

Review 1.  The reinstatement model of drug relapse: history, methodology and major findings.

Authors:  Yavin Shaham; Uri Shalev; Lin Lu; Harriet de Wit; Jane Stewart
Journal:  Psychopharmacology (Berl)       Date:  2002-10-26       Impact factor: 4.530

2.  Paradoxical sleep deprivation potentiates amphetamine-induced behavioural sensitization by increasing its conditioned component.

Authors:  Roberto Frussa-Filho; Michele Themis Moraes Gonçalves; Monica Levy Andersen; Nilza Pereira de Araujo; Cibele Cristina Chinen; Sergio Tufik
Journal:  Brain Res       Date:  2004-04-02       Impact factor: 3.252

Review 3.  Neurobiology of craving, conditioned reward and relapse.

Authors:  Friedbert Weiss
Journal:  Curr Opin Pharmacol       Date:  2005-02       Impact factor: 5.547

4.  Sleep deprivation impairs the extinction of cocaine-induced environmental conditioning in mice.

Authors:  L F Berro; A W Hollais; C L Patti; D F Fukushiro; E Mári-Kawamoto; F Talhati; J M Costa; K A Zanin; L B Lopes-Silva; L M Ceccon; R Santos; R Procópio-Souza; T F Trombin; T S Yokoyama; R Wuo-Silva; S Tufik; M L Andersen; R Frussa-Filho
Journal:  Pharmacol Biochem Behav       Date:  2014-05-13       Impact factor: 3.533

5.  Dopamine transporter-related effects of modafinil in rhesus monkeys.

Authors:  Monica L Andersen; Eileen Kessler; Kevin S Murnane; Jessica C McClung; Sergio Tufik; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2010-04-13       Impact factor: 4.530

6.  Effects of methamphetamine self-administration on actigraphy-based sleep parameters in rhesus monkeys.

Authors:  Monica L Andersen; Maylen P Diaz; Kevin S Murnane; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2012-12-22       Impact factor: 4.530

7.  Sleep disturbance as a universal risk factor for relapse in addictions to psychoactive substances.

Authors:  Kirk J Brower; Brian E Perron
Journal:  Med Hypotheses       Date:  2009-11-11       Impact factor: 1.538

  7 in total
  6 in total

1.  GABAA receptor positive allosteric modulators modify the abuse-related behavioral and neurochemical effects of methamphetamine in rhesus monkeys.

Authors:  Laís F Berro; Monica L Andersen; Sergio Tufik; Leonard L Howell
Journal:  Neuropharmacology       Date:  2017-05-08       Impact factor: 5.250

2.  Assessment of tolerance to the effects of methamphetamine on daytime and nighttime activity evaluated with actigraphy in rhesus monkeys.

Authors:  Laís F Berro; Monica L Andersen; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-06-07       Impact factor: 4.530

3.  Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) and R(-) MDMA on actigraphy-based daytime activity and sleep parameters in rhesus monkeys.

Authors:  Laís F Berro; Hannah Shields; Melis Odabas-Geldiay; Barbara O Rothbaum; Monica L Andersen; Leonard L Howell
Journal:  Exp Clin Psychopharmacol       Date:  2018-06-25       Impact factor: 3.157

4.  Potential use of actigraphy to measure sleep in monkeys: comparison with behavioral analysis from videography.

Authors:  Dong-Dong Qin; Shu-Fei Feng; Fei-Yu Zhang; Na Wang; Wen-Jie Sun; Yin Zhou; Teng-Fang Xiong; Xian-Lai Xu; Xiao-Ting Yang; Xiang Zhang; Xue Zhu; Xin-Tian Hu; Lei Xiong; Yun Liu; Yong-Chang Chen
Journal:  Zool Res       Date:  2020-07-18

5.  Methamphetamine-Induced Sleep Impairments and Subsequent Slow-Wave and Rapid Eye Movement Sleep Rebound in Male Rhesus Monkeys.

Authors:  Laís F Berro; John S Overton; James K Rowlett
Journal:  Front Neurosci       Date:  2022-04-07       Impact factor: 4.677

6.  The dual orexin receptor antagonist almorexant blocks the sleep-disrupting and daytime stimulant effects of methamphetamine in rhesus monkeys.

Authors:  Lais F Berro; Eliseu da Cruz Moreira-Junior; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2021-07-28       Impact factor: 4.852

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.